Janux Therapeutics Inc（JANX）の株式分析JANXJanux Therapeutics Inc

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed three bispecific platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). Its TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain. Its TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, Janux Therapeutics Inc is not a strong buy due to mixed signals from recent earnings and analyst ratings. The current price is $18.03, which is below the average analyst price target of $35, indicating potential upside. However, the company reported a disappointing Q2 EPS of -$0.35, missing expectations by $0.09, and has a negative net income of -$21,972,000 for Q2 2026, which raises concerns about profitability. The RSI is at 55.348, suggesting the stock is neither overbought nor oversold, and the recent 5-day change is +3.68%, showing some positive momentum. However, hedge funds are selling, with a 575.67% increase in selling activity over the last quarter, indicating a lack of confidence among institutional investors. Therefore, while there is potential for growth, the risks associated with current financial performance and market sentiment suggest holding rather than buying at this time.